Medicamen Biotech Peer Comparison

NSE: MEDICAMEQ | BSE: 531146

₹318.60

₹-3.15 (-0.98%)

As on 01-Oct-2026IST

Market cap

₹428 Cr

Revenue (TTM)

₹203 Cr

P/E Ratio

39.5

P/B Ratio

1.6

Div. Yield

0.3 %

Edit

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Market cap (₹ Cr)	428	36,515	33,680	30,875	14,713
Revenue (₹ Cr)	203	4,683	2,891	4,213	857
Net Profit (₹ Cr)	10.04	552.34	546.30	190.80	187.49
Net Margin (%)	4.87	11.55	18.23	4.49	21.32
RoE (%)	3.93	14.93	23.03	9.45	20.58
Price to Earnings	39.49	65.65	62.15	151.12	78.47
Price-To-Book	1.58	8.88	12.89	8.16	14.61

Income Statement (₹ Cr)

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Operating Revenue	202.62	4,683.37	2,890.80	4,212.50	857.13
Total Income	206.13	4,783.78	2,995.90	4,248.00	879.41
Total Expenditure	183.32	3,704.62	2,053.10	3,379.70	495.19
EBITDA	19.30	978.75	837.70	832.80	361.94
Depreciation	7.20	246.41	171.60	330.60	96.06
EBIT	12.09	732.34	666.10	502.20	265.89
Interest	3.17	92.01	24.40	253.30	36.75
Other Income	3.51	100.41	105.10	35.50	22.28
Exceptional Items	0.00	-20.61	-30.10	-11.20	0.00
Profit before Tax	12.43	720.14	716.70	273.20	251.42
Provision for Tax	2.38	167.80	170.40	82.40	63.93
Profit after Tax	10.04	552.34	546.30	190.80	187.49

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Shareholder's Funds	275.55	3,961.57	2,508.20	2,247.40	957.15
Minority Interest	0.79	3.84	-4.40	9.90	0.00
Non-Current Liabilities	8.52	1,293.60	154.00	3,961.30	426.03
Current Liabilities	87.92	627.13	450.70	1,238.90	123.87
Total Liabilities	297.15	4,766.23	2,713.41	5,689.20	1,273.62

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Non-Current Assets	92.79	3,128.95	1,176.30	5,416.90	737.24
Current Assets	223.73	1,674.92	1,566.60	937.40	321.90
Total Assets	297.15	4,766.23	2,713.41	5,689.20	1,273.62
Total Debt*	33.77	327.88	0.00	1,910.90	0.00
Net Current Assets	135.81	1,047.79	1,115.90	-301.50	198.03
Contingent Liabilities	--	88.77	10.59	83.80	0.13

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Cash From Operating Activities	-8.16	623.76	568.89	581.80	224.47
Cash Flow from Investing Activities	-1.40	-720.94	-303.16	-1,116.20	-181.88
Cash from Financing Activities	-1.47	-97.23	-334.03	543.10	-52.05
Net Cash Inflow / Outflow	-11.03	-194.41	-68.31	8.70	-9.45

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
ROCE (%)	5.77	20.50	31.53	19.02	30.20
ROE (%)	3.93	14.93	23.03	9.45	20.58
ROA (%)	3.00	10.35	18.64	2.83	13.49
EBIT Margin (%)	5.97	15.64	23.04	11.92	31.02
Net Margin (%)	4.87	11.55	18.23	4.49	21.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Revenue Growth (%)	24.66	21.27	14.29	30.90	20.18
EBIT Growth (%)	52.44	0.94	15.64	-16.88	26.22
Net Profit Growth (%)	37.69	3.43	5.38	-52.81	24.27
EPS Growth (%)	8.37	2.70	-30.51	-42.60	23.44
Book Value Growth (%)	2.99	16.71	17.68	16.93	19.36

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Price / Earnings	39.49	63.76	47.07	139.13	78.33
Price / Book Value	1.58	8.88	12.89	8.16	14.61
Dividend Yield (%)	0.32	0.04	1.02	0.00	0.14
EV/EBITDA	23.72	36.80	38.61	40.86	39.87
Market Cap (₹ Cr)	612.46	32,181.74	20,714.85	25,571.93	10,333.01

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debt to Equity	0.02	0.15	0.00	1.19	0.00
Short term debt to equity ratio	0.14	--	--	0.06	--
Current Ratio	2.54	2.67	3.48	0.76	2.60
Quick Ratio	1.75	2.54	3.38	0.68	2.56
Interest Coverage	4.92	8.83	30.37	2.08	7.84

	Medicamen Biotech	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debtors to sales (%)	40.38	8.78	3.83	13.16	2.43
Asset Turnover	0.61	0.88	0.99	0.62	0.62
Receivable days	139.40	25.07	12.27	41.48	8.30
Inventory Days	136.43	6.62	5.45	6.82	2.71
Payable days	226.08	79.17	134.04	135.60	142.28
Cash Conversion Cycle	49.75	-47.48	-116.32	-87.31	-131.27

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.